#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Progressive multiple sclerosis: from pathogenic mechanisms to treatment"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
 DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/0816cb6686751420365441adc6a28ced2d272f14/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
 DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
 DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "27794524"}

SET Evidence = "Multiple sclerosis is a chronic inflammatory disease of the
CNS leading to demyelination and neurodegeneration."
path(MESH:"Multiple Sclerosis") isA path(MESH:"Central Nervous System Diseases")
path(MESH:"Multiple Sclerosis") -> path(MESH:"Demyelinating Diseases")
path(MESH:"Multiple Sclerosis") -> path(MESH:"Neurodegenerative Diseases")

SET Evidence = "Results from immunological, genetic and histopathology studies of patients with
multiple sclerosis support the concept that autoimmunity
plays a major role in disease pathogenesis (McFarland
and Martin, 2007)"
path(MESH:Autoimmunity) -- path(MESH:"Multiple Sclerosis")

SET Evidence = "The course of multiple sclerosis is highly variable; nevertheless
in most patients, multiple sclerosis is characterized
by the onset of recurring clinical symptoms followed by
total or partial recovery, namely, the classic relapsingremitting
form of multiple sclerosis (RRMS)."
#RRMS: Multiple Sclerosis, Relapsing-Remitting
path(MESH:"Multiple Sclerosis") -> path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "One suggests that brain damage is driven by inflammatory processes similar
to those observed during RRMS; but that during progressive disease stages, a microenvironment is created within the CNS favouring homing and retention of inflammatory cells, ultimately causing disease-modifying therapies to become largely ineffective (Frischer et al., 2009)."
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") -> bp(GO:"inflammatory response")
bp(GO:"inflammatory response") neg bp(GO:"brain development")
bp(GO:"central nervous system development") pos bp(GO:"inflammatory response")
bp(GO:"inflammatory response") -> path(MESH:"Disease Resistance")

SET Evidence = "Although brain and spinal cord inflammation are present in
RRMS, SPMS, and PPMS its extent declines with age and
disease duration."
#secondary progressive multiple sclerosis (SPMS) - Multiple Sclerosis, Chronic Progressive
#primary progressive multiple sclerosis (PPMS) - Multiple Sclerosis, Chronic Progressive
SET MeSHAnatomy = "Brain"
SET Anatomy = "spinal cord"
path(MESH:"Multiple Sclerosis, Chronic Progressive") -> path(MESH:Inflammation)
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") -> path(MESH:Inflammation)
path(MESH:Aging) -| path(MESH:Inflammation)
path(MESH:"Disease Resistance") -> path(MESH:Inflammation)
UNSET MeSHAnatomy
UNSET Anatomy

SET Evidence = "Among potential candidates driving inflammation during progressive
multiple sclerosis, the role of B cells appears to be prominent,
particularly in the context of meningeal inflammation
(Magliozzi et al., 2007)."
#Meningitis - meningeal inflammation
path(MESH:"B-Lymphocytes") -- path(MESH:Meningitis)

SET Evidence = "B cell functions that could be of
relevance in progressive multiple sclerosis include: antibody
production, cytokine secretion, antigen presentation and
ectopic formation of follicle-like structures, a pathological
feature shared with other chronic inflammatory diseases
(Aloisi and Pujol-Borrell, 2006)."
#Tertiary Lymphoid Structures - Ectopic Lymphoid Follicles
SET Disease = "multiple sclerosis"
p(MESH:"B-Lymphocytes") -> path(MESH:"Antibody Formation")
p(MESH:"B-Lymphocytes") -> sec(a(MESH:Cytokines))
p(MESH:"B-Lymphocytes") -> path(MESH:"Antigen Presentation")
p(MESH:"B-Lymphocytes") -> path(MESH:"Tertiary Lymphoid Structures")
UNSET Disease

SET Evidence = "Furthermore, increased secretion
of pro-inflammatory cytokines such as lymphotoxin,
tumour necrosis factor alpha (TNF-alpha), and interleukin
(IL)-6, or deficient production of regulatory cytokines
including IL-10 or IL-35 may impact complement activation
and T cell function (Bar-Or et al., 2010)."
#LTA - lymphotoxin
#complex(p(HGNC:IL12A), p(HGNC:EBI3)) - IL-35
p(HGNC:TNF) isA a(MESH:Cytokines)
p(HGNC:LTA) isA a(MESH:Cytokines)
p(HGNC:IL6) isA a(MESH:Cytokines)
p(HGNC:IL10) reg a(MESH:Cytokines)
complex(p(HGNC:IL12A), p(HGNC:EBI3)) reg a(MESH:Cytokines)
p(HGNC:TNF) pos path(MESH:"Complement Activation")
p(HGNC:LTA) pos path(MESH:"Complement Activation")
p(HGNC:IL6) pos path(MESH:"Complement Activation")
p(HGNC:IL10) neg path(MESH:"Complement Activation")
complex(p(HGNC:IL12A), p(HGNC:EBI3)) neg path(MESH:"Complement Activation")
p(HGNC:TNF) pos act(p(MESH:"T-Lymphocytes"))
p(HGNC:LTA) pos act(p(MESH:"T-Lymphocytes"))
p(HGNC:IL6) pos act(p(MESH:"T-Lymphocytes"))
p(HGNC:IL10) neg act(p(MESH:"T-Lymphocytes"))
complex(p(HGNC:IL12A), p(HGNC:EBI3)) neg act(p(MESH:"T-Lymphocytes"))

SET Evidence = "Thus, this compartmental CNS B
cell immune response may be able to drive CNS injury
independent of peripheral immune activity (Lovato et al.,
2011)."
SET Anatomy = "central nervous system"
p(MESH:"B-Lymphocytes") -> path(MESH:"Wounds and Injuries")
path(MESH:Immunity) cnc act(p(MESH:"B-Lymphocytes"))

SET Evidence = "Follicle-like structures have recently been found in
the subarachnoid space of leptomeninges, close to inflamed
blood vessels. Composition of these infiltrates included:
proliferating B lymphocytes, plasma cells, helper T lymphocytes
and a network of follicular dendritic cells (Serafini
et al., 2004; Magliozzi et al., 2007)."
SET Anatomy = "subarachnoid space"
path(MESH:"Tertiary Lymphoid Structures") hasComponents list(a(MESH:"B-Lymphocytes"), a(MESH:"Plasma Cells"), a(MESH:"T-Lymphocytes, Helper-Inducer"), a(MESH:"Dendritic Cells, Follicular"))
UNSET Anatomy

SET Evidence = "Follicular dendritic cells within follicle-like
structure produce CXCL13, which is important for recruitment,
as well as maturation and antigenic selection of B
cells (Corsiero et al., 2012)."
a(MESH:"Dendritic Cells, Follicular") -> sec(p(HGNC:CXCL13))
p(HGNC:CXCL13) pos a(MESH:"B-Cell Maturation Antigen")
p(HGNC:CXCL13) pos bp(GO:"regulation of B cell chemotaxis")
p(HGNC:CXCL13) pos bp(GO:"B cell selection")

SET Evidence = "However, clonally-restricted B cells have been found in CSF from patients with RRMS
(Kuenz et al., 2008) indicating intrathecal clonal expansion of B cells."
SET Cell = "lymphocyte of B lineage"
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") -> path(CONSO:"Clonal Expansion")
UNSET Cell

SET Evidence = "Notably, follicle-
like structures are probably able to sustain a high level
of humoral response, as well as other autoimmune mechanisms
within the CNS, in a manner independent of peripheral
inflammation."
path(MESH:"Immunity, Humoral") cnc path(MESH:"Tertiary Lymphoid Structures")
SET Anatomy = "central nervous system"
path(MESH:Autoimmunity) cnc path(MESH:"Tertiary Lymphoid Structures")
UNSET Anatomy

SET Evidence = "In multiple sclerosis, cortical demyelination, neurodegeneration and atrophy
show positive correlation with diffuse inflammatory infiltrates and lymphoid follicle-like structure in leptomeninges, indicating immune activation in this compartment contributes to cortical pathology in multiple sclerosis (Lassmann et al., 2007; Magliozzi et al., 2007, 2010)."
SET Disease = "multiple sclerosis"
path(MESH:"Neurodegenerative Diseases") pos bp(GO:"inflammatory response")
path(MESH:"Neurodegenerative Diseases") pos path(MESH:"Tertiary Lymphoid Structures")
path(MESH:Atrophy) pos bp(GO:"inflammatory response")
path(MESH:Atrophy) pos path(MESH:"Tertiary Lymphoid Structures")
SET Anatomy = "cortex"
path(MESH:"Demyelinating Diseases") pos bp(GO:"inflammatory response")
path(MESH:"Demyelinating Diseases") pos path(MESH:"Tertiary Lymphoid Structures")
bp(GO:"inflammatory response") -> path(MESH:Pathology)
UNSET Anatomy
UNSET Disease

SET Evidence = "Moreover, in SPMS meningeal inflammation is associated
with damage to the glia limitants, and a gradient of neuronal
loss is observed that is greater in superficial cortical
layers nearer the pial surface than in inner cortical layers
(Magliozzi et al., 2010)."
#pial surface
SET Disease = "multiple sclerosis"
SET Anatomy = "cortex"
path(MESH:Meningitis) -> bp(GO:"neuron death")
UNSET Anatomy
UNSET Disease

SET Evidence = "Indeed, presence of follicle-like structure in patients with SPMS has
been associated with lower age at disease onset, more
severe disability and higher death rates (Magliozzi et al.,
2007, 2010; Howell et al., 2011)."
SET MeSHDisease = "Multiple Sclerosis, Chronic Progressive"
path(MESH:"Tertiary Lymphoid Structures") -| path(MESH:"Age of Onset")
path(MESH:"Tertiary Lymphoid Structures") => bp(GO:"neuron death")
UNSET MeSHDisease

SET Evidence = "In
both cases, diffuse meningeal inflammation and cortical
neuronal pathology may be significant contributors to clinical
progression, suggesting similar pathogenic mechanisms,
irrespective of a prior relapsing-remitting course or the presence of follicle-like structures (Choi et al., 2012)."
#both cases - PPMS and SPMS
path(MESH:Meningitis) -> path(MESH:"Multiple Sclerosis, Chronic Progressive")
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") cnc path(MESH:Meningitis)
path(MESH:"Tertiary Lymphoid Structures") cnc path(MESH:Meningitis)
SET Anatomy = "cortex"
path(MESH:Pathology) -> path(MESH:"Multiple Sclerosis, Chronic Progressive")
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") cnc path(MESH:Pathology)
path(MESH:"Tertiary Lymphoid Structures") cnc path(MESH:Pathology)
UNSET Anatomy

SET Evidence = "Furthermore, expression of EBV lytic
proteins BZLF1 and BERF1 was found to be restricted to
plasma cells located in active cortical lesions (Magliozzi
et al., 2013)"
#3783744 - BZLF1
#7707 - BERF1
SET Anatomy = "cortex"
path(MESH:"Epstein-Barr Virus Infections") hasComponents list(p(NCBIGENE:3783744, loc(MESH:"Plasma Cells")),p(NCBIGENE:7707, loc(MESH:"Plasma Cells")))
UNSET Anatomy

SET Evidence = "It is interesting to note that early lytic EBV
antigens elicited CD8-mediated immune responses, triggering
strong cytotoxic effects on brain tissue (Hislop et al.,
2007)."
path(MESH:"Epstein-Barr Virus Infections") => bp(GO:"CD8-positive, alpha-beta T cell differentiation involved in immune response")
SET MeSHAnatomy = "Brain"
bp(GO:"CD8-positive, alpha-beta T cell differentiation involved in immune response") => a(MESH:Cytotoxins)
UNSET MeSHAnatomy

SET Evidence = "Indeed, the most active cortical multiple sclerosis
lesions are crowded with CD8 + T cells and contain few
B cells or plasma cells, suggesting cortical inflammation
might correlate with reduction in EBV-infected B/plasma
cells numbers (Magliozzi et al., 2013)."
path(MESH:"Multiple Sclerosis") -> a(MESH:"CD8-Positive T-Lymphocytes")
SET Anatomy = "cortex"
SET Cell = {"lymphocyte of B lineage", "plasma cell"}
path(MESH:Inflammation) =| path(MESH:"Epstein-Barr Virus Infections")
UNSET Cell
UNSET Anatomy

SET Evidence = "Cytotoxic T lymphocytes release pro-inflammatory cytokines
such as TNF-alpha and interferon (IFN)-gamma, as well as
perforin, and granzymes A and B, among others (Huse
et al., 2008; Mizuno et al., 2008; Meuth et al., 2009)."
a(MESH:"T-Lymphocytes, Cytotoxic") -> sec(p(HGNC:TNF))
a(MESH:"T-Lymphocytes, Cytotoxic") -> sec(p(HGNC:IFNG))
a(MESH:"T-Lymphocytes, Cytotoxic") -> sec(p(HGNC:PRF1))
a(MESH:"T-Lymphocytes, Cytotoxic") -> sec(p(HGNC:GZMA))
a(MESH:"T-Lymphocytes, Cytotoxic") -> sec(p(HGNC:GZMB))

SET Evidence = "TNF-alpha for instance, can trigger cell death via the p55 receptor on neurons (Venters et al., 2000)."
#TNFRSF1A - TNF-alpha p55 receptor
p(HGNC:TNFRSF1A, loc(MESH:Neurons)) -> bp(GO:"neuron death")

SET Evidence = "IFN-gamma on the
other hand, increases glutamate neurotoxicity and calcium
influx into neurons through modulating the IFN-gamma/AMPA
GluR1 complex (Mizuno et al., 2008)."
p(HGNC:IFNG) neg bp(GO:"glutamate homeostasis")
SET Cell = "neuron"
complex(p(HGNC:IFNG), p(HGNCGENEFAMILY:"Glutamate ionotropic receptor AMPA type subunits")) reg bp(GO:"calcium ion import")
UNSET Cell

SET Evidence = "Perforin and granzyme
directly damage the membrane, causing sodium and
calcium influx that ultimately leads to energy breakdown
within the cell."
p(HGNC:PRF1) -> bp(GO:"sodium ion import across plasma membrane")
p(HGNC:GZMA) -> bp(GO:"sodium ion import across plasma membrane")
p(HGNC:GZMB) -> bp(GO:"sodium ion import across plasma membrane")
p(HGNC:PRF1) -> bp(GO:"calcium ion import")
p(HGNC:GZMA) -> bp(GO:"calcium ion import")
p(HGNC:GZMB) -> bp(GO:"calcium ion import")
bp(GO:"calcium ion import") -> path(MESH:"Energy Metabolism")
bp(GO:"sodium ion import across plasma membrane") -> path(MESH:"Energy Metabolism")

SET Evidence = "Furthermore, interaction of Fas
antigen on cytotoxic T lymphocyte with Fas ligand on neurons
is an additional mechanism activating the intracellular
caspase cascade causing axonal/neuronal damage (Medana
et al., 2000; Giuliani et al., 2003)."
SET Cell = "neuron"
p(HGNC:FASLG) -> composite(a(MESH:"T-Lymphocytes, Cytotoxic"), p(HGNC:FAS))
composite(a(MESH:"T-Lymphocytes, Cytotoxic"), p(HGNC:FAS)) -> act(a(MESH:Caspases))
act(a(MESH:Caspases)) -> path(MESH:"Nerve Degeneration")
UNSET Cell

SET Evidence = "Active demyelination and neurodegeneration have also been linked to microglial activation in early lesions with accumulation of macrophages in injured tissues (Lassmann, 2014)."
path(MESH:"Nerve Degeneration") -- bp(GO:"microglial cell activation")
path(MESH:"Demyelinating Diseases") -- bp(GO:"microglial cell activation")
#in injured tissues
bp(GO:"microglial cell activation") => a(MESH:Macrophages)

SET Evidence = "Under normal circumstances, inactive microglia contributes to neuronal compartment
homeostasis."
SET Cell = "neuron"
bp(GO:"microglial cell activation") -| bp(GO:"compartment boundary maintenance")
UNSET Cell

SET Evidence = "However, it also plays a central role in autoimmune disorders as it can sustain ongoing inflammation once activated (Correale, 2014)."
#It - microglia
bp(GO:"microglial cell activation") -- path(MESH:Inflammation)
bp(GO:"microglial cell activation") -- path(MESH:"Autoimmune Diseases")

SET Evidence = "In multiple sclerosis, activated microglia damage oligodendrocytes
through different mechanisms including: secretion of pro-inflammatory cytokines such as IL-1, IL-6, TNF-alpha, and IFN-gamma, phagocytic activity, and presentation of antigens via MHC Class II to CD4+ T cells (Correale, 2014)."
bp(GO:"microglial cell activation") =| a(MESH:Oligodendroglia)
bp(GO:"microglial cell activation") -> sec(p(HGNC:IL1A))
bp(GO:"microglial cell activation") -> sec(p(HGNC:IL6))
bp(GO:"microglial cell activation") -> sec(p(HGNC:TNF))
bp(GO:"microglial cell activation") -> sec(p(HGNC:IFNG))
bp(GO:"microglial cell activation") -> act(a(MESH:Phagocytes))
bp(GO:"microglial cell activation") pos bp(GO:"regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II")
p(HGNC:IL1A) =| a(MESH:Oligodendroglia)
p(HGNC:IL6) =| a(MESH:Oligodendroglia)
p(HGNC:TNF) =| a(MESH:Oligodendroglia)
p(HGNC:IFNG) =| a(MESH:Oligodendroglia)
act(a(MESH:Phagocytes)) =| a(MESH:Oligodendroglia)
bp(GO:"regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II") =| a(MESH:Oligodendroglia)

SET Evidence = "In addition, direct damage to neurons occurs through reactive
oxygen and nitrogen species (ROS/NRS) produced by microglia, inducing mitochondrial dysfunction"
a(CHEBI:"reactive oxygen species") => path(MESH:"Mitochondrial Diseases")
a(CHEBI:"reactive nitrogen species") => path(MESH:"Mitochondrial Diseases")
a(MESH:Microglia) => sec(a(CHEBI:"reactive oxygen species"))
a(MESH:Microglia) => sec(a(CHEBI:"reactive nitrogen species"))

SET Evidence = "It is interesting to note that activated microglia possess
a puzzling array of neuroprotective functions as well, including debris phagocytosis and clearance, elaboration of growth factors and neuronal circuit-shaping (Arnett et al., 2001; Kotter et al., 2001; Correale, 2014)."
bp(GO:"microglial cell activation") -> path(MESH:Neuroprotection)
bp(GO:"microglial cell activation") -> path(MESH:Phagocytosis)
bp(GO:"microglial cell activation") -> bp(GO:"neuron remodeling")

SET Evidence = "Laquinimod, an emerging oral medication for multiple sclerosis (see below) with significant CNS impact, reduces astrocyte activation (Bruck et al., 2012), and inhibits microglial activation in human brain cell cultures."
a(CHEBI:laquinimod) -| path(MESH:"Multiple Sclerosis")
a(CHEBI:laquinimod) neg bp(GO:"central nervous system development")
a(CHEBI:laquinimod) -| bp(GO:"astrocyte activation")
SET Species = "9606"
SET MeSHAnatomy = "Brain"
a(CHEBI:laquinimod) =| bp(GO:"microglial cell activation")
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "It reduces both pro- and anti-inflammatory cytokine levels, while growth factor secretion remains high."
# It - laquinimod
a(CHEBI:laquinimod) -| a(MESH:"Anti-Inflammatory Agents")
a(CHEBI:laquinimod) cnc sec(a(MESH:"Growth Differentiation Factors"))


SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"

SET Evidence = "Furthermore, a reduction in microglial/macrophage density has been
observed in experimental autoimmune encephalomyelitis (EAE) animals treated with laquinimod, ultimately preventing axonal injury and demyelination progression (Mishra et al., 2014)."
SET Cell = {"microglial cell", "macrophage"}
a(CHEBI:laquinimod) -| path(MESH:"Population Density")
UNSET Cell
a(CHEBI:laquinimod) -| path(MESH:"Diffuse Axonal Injury")
a(CHEBI:laquinimod) -| path(MESH:"Demyelinating Diseases")

SET Evidence = "Recent investigations have demonstrated that in chronic phases of EAE, astrocyte depletion
ameliorates disease severity, a deleterious effects mediated by preferential expression of 4-galactosyltransferase 5 and 6 (B4GALT5 and B4GALT6; Mayo et al., 2014)."
bp(GO:"astrocyte activation") =| path(MESH:Disease)
p(HGNC:B4GALT5) => path(MESH:Disease)
p(HGNC:B4GALT6) => path(MESH:Disease)

SET Evidence = "Notably, in human multiple sclerosis lesions BAGALT6 is expressed by reactive astrocytes."
SET Species = "9606"
SET Disease = "multiple sclerosis"
bp(GO:"astrocyte activation") -> p(HGNC:B4GALT6)
UNSET Disease
UNSET Species

SET Evidence = "These enzymes synthesize the signalling molecule lactosylceramide (LacCer), which is
significantly increased in the CNS during progressive phases of EAE."
#These enzymes : B4GALT5 and B4GALT6
p(HGNC:B4GALT5) -> a(PUBCHEM:20057304)
p(HGNC:B4GALT6) -> a(PUBCHEM:20057304)
SET Anatomy = "central nervous system"
path(MESH:"Encephalomyelitis, Autoimmune, Experimental") => a(PUBCHEM:20057304)
UNSET Anatomy

SET Evidence = "LacCer promotes astrocyte activation, leading to granulocyte-macrophage colony-stimulating factor (GMCSF, encoded by CSF2) and CCL2 gene induction, consequently activating microglia and causing infiltration of monocytes from the peripheral blood."
a(PUBCHEM:20057304) => bp(GO:"astrocyte activation")
bp(GO:"astrocyte activation") => g(HGNC:CSF2)
bp(GO:"astrocyte activation") => g(HGNC:CCL2)
g(HGNC:CSF2) -> bp(GO:"microglial cell activation")
g(HGNC:CCL2) -> bp(GO:"microglial cell activation")
bp(GO:"microglial cell activation") -> bp(GO:"monocyte migration into blood stream")

SET Evidence = "Remarkably, inhibition of B4galt6 in mice suppresses disease progression and
neurodegeneration in EAE (Mayo et al., 2014)."
SET Species = "10090"
p(HGNC:B4GALT6) -> path(MESH:"Encephalomyelitis, Autoimmune, Experimental")
p(HGNC:B4GALT6) -> path(MESH:"Neurodegenerative Diseases")
UNSET Species

UNSET MeSHDisease

SET Evidence = "Evidence from both imaging and pathology suggest that the inflammatory demyelinating
process in early multiple sclerosis drives a pathogenic cascade of events causing neurodegeneration, which in turn is further amplified by brain ageing, microglial activation and accumulated disease burden (Popescu and Lucchinetti, 2012; Mahad et al., 2015)."
path(MESH:"Demyelinating Diseases") -> path(MESH:"Neurodegenerative Diseases")
bp(GO:"microglial cell activation") -> path(MESH:"Neurodegenerative Diseases")
path(MESH:Aging) -> path(MESH:"Neurodegenerative Diseases")

SET Evidence = "Because pathology findings and number of transected axons correlate with degree of
inflammation in acute multiple sclerosis lesions (Trapp et al., 1998; Frischer et al., 2009), great interest has been focused on neurotoxic products released by innate immune cells, particularly ROS, RNS and nitric oxide (NO) produced by macrophages, microglia, and astrocytes, both in multiple sclerosis and in EAE (Haider et al., 2011)."
SET Disease = "multiple sclerosis"
bp(GO:"activation of innate immune response") => sec(a(CHEBI:"reactive oxygen species"))
bp(GO:"activation of innate immune response") => sec(a(CHEBI:"reactive nitrogen species"))
bp(GO:"activation of innate immune response") => sec(a(CHEBI:"nitric oxide"))
a(CHEBI:"reactive oxygen species") isA a(MESH:Neurotoxins)
a(CHEBI:"reactive nitrogen species") isA a(MESH:Neurotoxins)
a(CHEBI:"nitric oxide") isA a(MESH:Neurotoxins)
a(MESH:Macrophages) => a(CHEBI:"reactive oxygen species")
a(MESH:Macrophages) => a(CHEBI:"reactive nitrogen species")
a(MESH:Macrophages) => a(CHEBI:"nitric oxide")
a(MESH:Microglia) => a(CHEBI:"reactive oxygen species")
a(MESH:Microglia) => a(CHEBI:"reactive nitrogen species")
a(MESH:Microglia) => a(CHEBI:"nitric oxide")
a(MESH:Astrocytes) => a(CHEBI:"reactive oxygen species")
a(MESH:Astrocytes) => a(CHEBI:"reactive nitrogen species")
a(MESH:Astrocytes) => a(CHEBI:"nitric oxide")
UNSET Disease

SET Evidence  = "NO has been shown to cause irreversible conduction blockade in axons and to drive spinal cord degeneration in rats (Smith et al., 2001)."
SET Species = "10114"
a(CHEBI:"nitric oxide") =| path(MESH:"Neural Conduction")
a(CHEBI:"nitric oxide") =| bp(GO:"spinal cord development")
UNSET Species

SET Evidence = "In turn, scavengers reducing ROS and RNS levels in EAE were able to attenuate focal
axonal degeneration without altering the number of immune cells is EAE lesions."
a(MESH:"Free Radical Scavengers") =| a(CHEBI:"reactive oxygen species")
a(MESH:"Free Radical Scavengers") =| a(CHEBI:"reactive nitrogen species")
a(MESH:"Free Radical Scavengers") cnc path(MESH:Immunity)

SET Evidence = "Neuronal cell bodies in deeper layers of the cortex show evidence of impaired functional
activity of mitochondrial respiratory chain complexes (Campbell et al., 2011), as well as alterations in motor proteins (encoded by nuclear DNA) responsible for the movement of the mitochondria from cell body to axons (Campbell et al., 2014)."
#in case of disease
SET Anatomy = "cortex"
path(MESH:"Multiple Sclerosis") -| act(p(MESH:"Electron Transport Chain Complex Proteins"))
path(MESH:"Multiple Sclerosis") -| p(MESH:"Molecular Motor Proteins")
p(MESH:"Molecular Motor Proteins") => tloc(p(MESH:Mitochondria),fromLoc(GO:"cell body"),toLoc(GO:axon))
UNSET Anatomy

SET Evidence = "First, mitochondrial dysfunction results in energy deficiency, which in mild forms
will induce functional disturbances in the absence of structural damage."
path(MESH:"Mitochondrial Diseases") -| path(MESH:"Energy Metabolism")
path(MESH:"Mitochondrial Diseases") -| act(p(MESH:Mitochondria))

SET Evidence = "However, when mitochondrial injury surpasses a certain threshold, energy deficiency will lead to axonal degeneration and cell death (Friese et al., 2014)."
path(MESH:"Energy Metabolism") =| path(MESH:"Nerve Degeneration")
path(MESH:"Energy Metabolism") =| bp(GO:"cell death")

SET Evidence = "Second, mitochondrial injury may amplify oxidative stress through release of oxygen radicals generated as a result of impaired respiratory chain function, thus establishing a vicious
cycle of tissue destruction (Murphy, 2009)"
path(MESH:"Mitochondrial Diseases") -| act(p(MESH:"Electron Transport Chain Complex Proteins"))
act(p(MESH:"Electron Transport Chain Complex Proteins")) =| sec(a(CHEBI:"reactive oxygen species"))
sec(a(CHEBI:"reactive oxygen species")) => path(MESH:"Oxidative Stress")

SET Evidence = "In addition, non-toxic ferric iron is released into the extracellular
space from damaged oligodendrocytes in multiple sclerosis lesions, where it undergoes transformation to the divalent ferrous form, further increasing ROS toxicity (Hametner et al., 2013)."
SET Disease = "multiple sclerosis"
a(MESH:Oligodendroglia) =| a(CHEBI:"iron(3+)", loc(GO:"extracellular space"))
a(CHEBI:"iron(3+)", loc(GO:"extracellular space")) -> a(CHEBI:"iron(2+)", loc(GO:"extracellular space"))
a(CHEBI:"iron(2+)", loc(GO:"extracellular space")) => a(CHEBI:"reactive oxygen species")
UNSET Disease

SET Evidence = "If axonal Na+ rises above its nominal concentration, the Na+ /Ca2+ exchanger, normally exchanging axoplasmic Ca2+ for extracellular Na+ , will operate in a reverse Ca2+ importing mode."
#above its norminal level
a(CHEBI:"sodium(1+)", loc(GO:axon)) => a(CHEBI:"calcium(2+)", loc(GO:axon))
p(MESH:"Sodium-Calcium Exchanger") =| a(CHEBI:"calcium(2+)", loc(GO:axon))
p(MESH:"Sodium-Calcium Exchanger") => a(CHEBI:"sodium(1+)", loc(GO:axon))
p(MESH:"Sodium-Calcium Exchanger") =| a(CHEBI:"calcium(2+)", loc(GO:"extracellular space"))

SET Evidence = "With increasing electrical traffic, axoplasmic Ca2+ will rise and eventually a Ca2+-
mediated degenerative response will be initiated (Trapp and Stys, 2009)."
a(CHEBI:"calcium(2+)", loc(GO:axon)) => path(MESH:"Neurodegenerative Diseases")

SET Evidence = "Excess of intra-axonal Ca2+ may stimulate a variety of Ca2+ dependent catabolic enzyme systems,
including proteases, phospholipases and calpains, ultimately leading to progressive intra-axonal proteolytic degradation of cytoskeletal proteins and axonal degeneration (Stys, 2005)."
a(CHEBI:"calcium(2+)", loc(GO:axon)) -> a(MESH:Calpain)
a(CHEBI:"calcium(2+)", loc(GO:axon)) -> a(MESH:Phospholipases)
a(MESH:Calpain) => path(MESH:"Nerve Degeneration")
a(MESH:Phospholipases) => path(MESH:"Nerve Degeneration")
a(MESH:Calpain) => deg(p(MESH:"Cytoskeletal Proteins"))
a(MESH:Phospholipases) => deg(p(MESH:"Cytoskeletal Proteins"))

SET Evidence = "Moreover, intracellular Ca2+ increase results in changes in microtubules and neurofilament phosphorylation, ultimately causing cytoskeleton breakdown (Nicholls, 2004)."
a(CHEBI:"calcium(2+)", loc(GO:axon)) neg p(MESH:"Microtubule Proteins", pmod(Ph))
a(CHEBI:"calcium(2+)", loc(GO:axon)) neg p(MESH:"Neurofilament Proteins", pmod(Ph))
p(MESH:"Microtubule Proteins", pmod(Ph)) reg path(MESH:Cytoskeleton)
p(MESH:"Neurofilament Proteins", pmod(Ph)) reg path(MESH:Cytoskeleton)


SET Evidence = "Axons that lack Na+ /K + ATPase cannot exchange axoplasmic Na+ for K+ and are incapable of repolarizing the axolemma."
p(MESH:"Sodium-Potassium-Exchanging ATPase") reg bp(GO:"membrane repolarization")

SET Evidence = "Redistribution of voltage-gated Ca2+ channels, transient potential receptor melastatin 4 (TRPM4), and
acid-sensing ion channel1 (ASIC1) induce neuroaxonal Ca2+ overload, eliciting deleterious effects on axons (Friese et al., 2014)."
p(HGNC:TRPM4) -| bp(GO:"positive regulation of calcium ion import")
p(MESH:"Calcium Channels") -| bp(GO:"positive regulation of calcium ion import")
p(HGNC:ASIC1) -| bp(GO:"positive regulation of calcium ion import")

SET Evidence = "Excitotoxicity is caused mainly by sustained activation of glutamate receptors
and subsequent massive influx of Ca2+ into viable neurons."
act(p(MESH:"Receptors, Glutamate")) -> path(CONSO:Excitotoxicity)
bp(GO:"positive regulation of calcium ion import") -> path(CONSO:Excitotoxicity)

#######code for Subpial cortical
SET Evidence = "Subpial cortical demyelination appears to be specific to multiple sclerosis, as it is not present in any other inflammatory, neurodegenerative or metabolic disease affecting the cortex and meninges (Fischer et al., 2013)."


#######white matter lensions?
SET Evidence = "Subpial cortical lesions lack many of the pathologic hallmarks found in white
matter lesions such as: bloodâbrain barrier breakdown, immune cell infiltrates, perivascular cuffs, loss of oligodendrocyte progenitor cells or complement activation (Dutta and Trapp, 2014)."

SET Evidence = "MRI studies revealed more pronounced grey matter and central
atrophy in males, and more advanced white matter atrophy in females (Antulov et al., 2009)."
#with respect to PPMS
SET Gender = "Male"
SET Anatomy = "central nervous system gray matter layer"
path(MESH:"Multiple Sclerosis, Chronic Progressive") -> path(MESH:Atrophy)
UNSET Anatomy
UNSET Gender
SET Gender = "Female"
SET Anatomy = "central nervous system white matter layer"
path(MESH:"Multiple Sclerosis, Chronic Progressive") -> path(MESH:Atrophy)
UNSET Anatomy
UNSET Gender

SET Evidence = "Increased sex hormone levels in females may protect against grey matter atrophy
(Cutter et al., 2006). In contrast, testosterone was shown to amplify oligodendrocyte excitotoxicity, potentially
limiting remyelination (Caruso et al., 2004)."
SET Gender = "Female"
SET Anatomy = "central nervous system gray matter layer"
p(MESH:"Gonadal Steroid Hormones") =| path(MESH:Atrophy)
UNSET Anatomy
UNSET Gender
p(MESH:Testosterone) => path(CONSO:Excitotoxicity)

SET Evidence = "Global NAA measured across the whole brain is abnormally low in multiple sclerosis"
#N-acetylaspartate (NAA)
path(MESH:"Multiple Sclerosis") =| a(PUBCHEM:	65065)

SET Evidence = "Because NAA is detected almost exclusively in neurons and their processes,
decreased levels of this metabolite have been interpreted as evidence of axonal injury."
a(PUBCHEM:	65065) -- path(MESH:"Nerve Degeneration")

######how to code for NAA/Cr ratio and for healty control
SET Evidence = "Whole brain MRS has successfully shown significant reduction in both NAA and
NAA/creatine (NAA/Cr) ratio, in clinically isolated syndrome and RRMS, compared to healthy controls."
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") =| a(PUBCHEM:	65065)

SET Evidence = "Notably, spinal cord grey matter atrophy seems to contribute more to patient
disability than spinal cord white matter or brain grey matter atrophy (Schlaeger et al., 2014)."
SET Anatomy = "spinal cord gray commissure"
path(MESH:Atrophy) -> path(MESH:"Developmental Disabilities")
UNSET Anatomy

SET Evidence = "The mitoxantrone in multiple sclerosis (MIMS) study was a double-blind phase II study of mitoxantrone in patients with SPMS with and without relapses (Hartung et al., 2002)."
a(PUBCHEM:4212) -| path(MESH:"Multiple Sclerosis")

SET Evidence = "Unfortunately, risk of serious side effects such as cardiomyopathy and treatment-related acute leukaemia has substantially limited indication in clinical practice (Goodin et al., 2003)."
a(PUBCHEM:4212) -> path(MESH:Cardiomyopathies)
a(PUBCHEM:4212) -> path(MESH:"Leukemia, Promyelocytic, Acute")

SET Evidence = "Several phase III clinical trials using IFNbeta1a and IFNbeta1b in SPMS did not show permanent disability delay, but did reduce relapses risk (SPECTRIMS Study Group, 2001; Cohen et al., 2002; Andersen et al., 2004; Panitch et al.,2004)."
a(PUBCHEM:223370366) -| path(MESH:"Developmental Disabilities")
a(PUBCHEM: 363907627) -| path(MESH:"Developmental Disabilities")
a(PUBCHEM:223370366) =| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")
a(PUBCHEM: 363907627) =| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "Natalizumab did show some positive effects on upper limb function, but
did not slow down disability accumulation compared to rates observed in the placebo group (NCT01416181)."
a(PUBCHEM:135314782) cnc path(MESH:"Developmental Disabilities")

SET Evidence = "Ocrelizumab is a fully humanized monoclonal antibody that depletes B cells via antibody-dependent cell-mediated toxicity, more than complement-dependent cytotoxicity, which could reduce infusion-related toxic side effects (Buttmann, 2010)."
a(PUBCHEM: 47206937) => bp(GO:"antibody-dependent cellular cytotoxicity")
bp(GO:"antibody-dependent cellular cytotoxicity") -| a(MESH:"B-Lymphocytes")

SET Evidence = "Thus, ocrelizumab becomes the first agent to have shown positive results in pivotal studies in PPMS (NCT 1194570)."
a(PUBCHEM: 47206937) =| path(MESH:"Multiple Sclerosis, Chronic Progressive")

SET Evidence = "Recently, two studies reported protective properties of MitoQ, a specific inhibitor for
mitochondrial ROS production, in EAE (Davies et al.,2013)."
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
a(PUBCHEM:11388331) =| a(CHEBI:"reactive oxygen species", loc(GO:mitochondrion))
UNSET MeSHDisease

SET Evidence = "Because levels of inflammation were not affected by MitoQ, it is conceivable that increased mitochondrial protection against ROS is sufficient to reduce axonal damage."
a(PUBCHEM:11388331) cnc path(MESH:Inflammation)
a(PUBCHEM:11388331) =| path(MESH:"Nerve Degeneration")

SET Evidence = "The antioxidant idebenone was proven to be beneficial in Leberâs hereditary optic neuropathy, a disorder caused by mitochondrial defects."
a(PUBCHEM:3686) isA a(MESH:Antioxidants)
a(PUBCHEM:3686) =| path(MESH:"Optic Atrophy, Hereditary, Leber")
path(MESH:"Optic Atrophy, Hereditary, Leber") isA path(MESH:"Mitochondrial Diseases")

SET Evidence = "However, in EAE, idebenone failed to affect disease incidence or onset when applied preventively,
or to reduce disease severity when applied therapeutically."
a(PUBCHEM:3686) cnc path(MESH:"Encephalomyelitis, Autoimmune, Experimental")

SET Evidence = "In EAE systemic administration of flecainamide (Bechtold et al., 2004), or
Na+ channel-blocking anticonvulsants (lamotrigine, phenytoin, carbamazepine) (Bechtold et al., 2004, 2006) reduced
neurological disability."
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
a(PUBCHEM:3878) -| path(MESH:"Neurologic Manifestations")
a(PUBCHEM:1775) -| path(MESH:"Neurologic Manifestations")
a(PUBCHEM:2554) -| path(MESH:"Neurologic Manifestations")
UNSET MeSHDisease

SET Evidence = "However, clinical trials of lamotrigine in patients with progressive multiple sclerosis did not
show advantages over placebo with respect to neuroprotection (Hayton et al., 2012)."
a(PUBCHEM:3878) cnc path(MESH:"Multiple Sclerosis")

SET Evidence = "Blocking these ion channels with amiloride or glibenclamide, respectively could be a new approach, as they provided neuroprotection in EAE and decreased neuronal and oligodendrocyte damage (Friese et al., 2007; Schattling et al., 2012)."
#there channels - ASIC1 and TRPM4
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
a(PUBCHEM:16231) =| p(HGNC:ASIC1)
a(PUBCHEM:16231) =| p(HGNC:TRPM4)
a(PUBCHEM:3488) =| p(HGNC:ASIC1)
a(PUBCHEM:3488) =| p(HGNC:TRPM4)
a(PUBCHEM:16231) -> path(MESH:Neuroprotection)
a(PUBCHEM:3488) -> path(MESH:Neuroprotection)
a(PUBCHEM:16231) -> a(MESH:Oligodendroglia)
a(PUBCHEM:3488) -> a(MESH:Oligodendroglia)
a(PUBCHEM:16231) -| path(MESH:"Nerve Degeneration")
a(PUBCHEM:3488) -| path(MESH:"Nerve Degeneration")

#####Don't understand the relationship between Glut receptor and NBQX
SET Evidence = "Treatment with the AMPA/kainate glutamate receptor NBQX decreased neurological disability, increased oligodendrocyte survival and reduced axonal damage in EAE (Pitt et al., 2000)."
a(PUBCHEM:3272524) -| path(MESH:"Nerve Degeneration")
a(PUBCHEM:3272524) -> a(MESH:Oligodendroglia)

UNSET MeSHDisease

 SET Evidence = "GDNF (glial-cell-line derived neurotrophic factor), IGF1, and BDNF are implicated in
trophic support provided for axons by oligodendrocytes (Wilkins et al., 2003), which one would predict would be
deficient in multiple sclerosis."
a(MESH:Oligodendroglia) => sec(p(HGNC:GDNF))
a(MESH:Oligodendroglia) => sec(p(HGNC:IGF1))
a(MESH:Oligodendroglia) => sec(p(HGNC:BDNF))
p(HGNC:GDNF) -- bp(GO:"axon development")
p(HGNC:IGF1) -- bp(GO:"axon development")
p(HGNC:BDNF) -- bp(GO:"axon development")

SET Evidence = "Interestingly, some immunomodulatory agents used for multiple sclerosis, namely IFN-beta and glatiramer
acetate have been shown to increase serum or immune cell levels of BDNF in patients with multiple sclerosis,
suggested as a possible mechanism of action for these therapies (Kalinowska-Lyszczarz and Losy, 2012)."
SET Disease = "multiple sclerosis"
a(PUBCHEM:223370366) -> p(MESH:Serum)
a(PUBCHEM:3081884) -> p(MESH:Serum)
a(PUBCHEM:223370366) -> p(HGNC:BDNF)
a(PUBCHEM:3081884) -> p(HGNC:BDNF)
UNSET Disease

SET Evidence = "Also laquinimod has neuroprotective potential that may depend, at least in part, on its effects on astrocytes and microglia (Bruck et al., 2012; Mishra et al., 2014)."
a(PUBCHEM:54677946) isA a(MESH:"Neuroprotective Agents")
a(PUBCHEM:54677946) -- a(MESH:Microglia)
a(PUBCHEM:54677946) -- a(MESH:Astrocytes)

SET Evidence = "MN-166 (ibudilast) is a non-selective phosphodiesterase inhibitor that suppresses pro-inflammatory cytokines, promotes neurotrophic factors, and attenuates activated glial cell (Suzumura et al., 2003; Feng et al., 2004)."
a(PUBCHEM:3671) => a(MESH:"Nerve Growth Factors")
a(PUBCHEM:3671) =| bp(GO:"glial cell activation")

SET Evidence = "It is known that DMF reduces oxidative stress related to neuronal death and myelin damage, via
the Nrf2 pathway, making DMF a potential therapeutic option for progressive multiple sclerosis (Strassburger-
Krogias et al., 2014)."
a(PUBCHEM:637568) -> p(HGNC:NFE2L2)
p(HGNC:NFE2L2) -| path(MESH:"Oxidative Stress")
path(MESH:"Oxidative Stress") -- bp(GO:"neuron death")
path(MESH:"Oxidative Stress") neg bp(GO:"myelin maintenance")

SET Evidence = "Masitinib is a selective tyrosine kinase inhibitor controlling mast cell degranulation, NO-mediated damage, and dendritic cell activity (Dubreuil et al., 2009)."
a(PUBCHEM:10074640) =| p(MESH:"Receptor Protein-Tyrosine Kinases")
a(PUBCHEM:10074640) reg bp(GO:"mast cell degranulation")
a(PUBCHEM:10074640) reg bp(GO:"nitric oxide mediated signal transduction")
a(PUBCHEM:10074640) reg bp(GO:"dendritic cell homeostasis")

SET Evidence = "LINGO1, a CNS-specific membrane glycoprotein that suppresses oligodendrocyte differentiation
and myelination, is possibly involved in failure of remyelination and axonal repair in multiple sclerosis
(Yong, 2009); blockade of this protein may therefore be effective in promoting remyelination in a clinical setting."
p(HGNC:LINGO1) =| bp(GO:"oligodendrocyte differentiation")
p(HGNC:LINGO1) =| bp(GO:myelination)
path(MESH:"Multiple Sclerosis") pos p(HGNC:LINGO1)

SET Evidence = "BIIB033, a fully human monoclonal antibody that selectively antagonizes
LINGO1, was found to be safe and well-tolerated in phase 1 studies (Tran et al., 2014)."
#Phase I
a(PUBCHEM:310264704) =| p(HGNC:LINGO1)
